Projects per year
Acute Promyelocytic Leukemia is caused by expression of the oncogenic Promyelocytic Leukemia (PML)–Retinoic Acid Receptor Alpha (RARA) fusion protein. Therapy with arsenic trioxide results in degradation of PML-RARA and PML and cures the disease. Modification of PML and PML-RARA with SUMO and ubiquitin precedes ubiquitin-mediated proteolysis. To identify additional components of this pathway, we performed proteomics on PML bodies. This revealed that association of p97/VCP segregase with PML bodies is increased after arsenic treatment. Pharmacological inhibition of p97 altered the number, morphology, and size of PML bodies, accumulated SUMO and ubiquitin modified PML and blocked arsenic-induced degradation of PML-RARA and PML. p97 localized to PML bodies in response to arsenic, and siRNA-mediated depletion showed that p97 cofactors UFD1 and NPLOC4 were critical for PML degradation. Thus, the UFD1-NPLOC4-p97 segregase complex is required to extract poly-ubiquitinated, poly-SUMOylated PML from PML bodies, prior to degradation by the proteasome.
|Number of pages||19|
|Journal||Journal of Cell Biology|
|Publication status||Published - 28 Feb 2023|
- Protein homeostasis
ASJC Scopus subject areas
- Cell Biology
FingerprintDive into the research topics of 'The p97/VCP segregase is essential for arsenic induced degradation of PML and PML-RARA'. Together they form a unique fingerprint.
Establishing the Basis for Selectivity in the SUMO Spray (Investigator Award)
1/02/20 → 31/01/25
Harnessing the PML-SUMO-RNF4 Axis for Cancer Therapy (Programme Grant)
1/12/16 → 30/09/22